Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2646 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-04-18 (news-pharm.ru)
In the Russian Federation, the 2nd analogue of Spinraza is registered ⋆
"Biocad" received a registration certificate for a product for healing spinal muscle atrophy - Nusinersen. This is the 2nd analogue registered in
Read more
2025-04-15 (cmoney.tw)
The EU approves Biogen and Eisai's new Alzheimer's drug Leqembi, creating a new situation for treatment!
Biogen and Eisai's Alzheimer's drug Leqembi, approved by the European Commission, will bring new hope for early stage patients.
Read more
2025-04-01 (directorstalkinterviews.com)
Biogen Inc. (BIIB): Potential 46% Upside Amid Strategic Product Expansion
Biogen Inc. (BIIB): Potential 46% Upside Amid Strategic Product Expansion
Read more
2025-02-25 (openpr.com)
Alzheimer Drug Market to Witness Impressive Growth by 2032: Biogen, Eli Lilly, Roche, Eisai, Novartis
Press release - HTF Market Intelligence Consulting Private Limited - Alzheimer Drug Market to Witness Impressive Growth by 2032: Biogen, Eli Lilly, Roche, Eisai, Novartis - published on openPR.com
Read more
2025-02-12 (optionfinance.fr)
AIG, Barrick Gold, Biogen, Kraft Heinz ... The values to follow today at Wall Street | Funds
(AOF) - AIG The American International Group insurer has unveiled higher profits than expected in the fourth quarter. He recorded a net profit of $ 898 million, or $ 1.43 per share, against a net profit of $ 86 million, or 12 cents per share, u
Read more
2025-02-12 (pharmabiz.net)
Biogen with decrease of -2.2% in sales -
The owner of the Super Caro Spinraza medicine published today, Wednesday, February 12, the balance corresponding to its 2024 year the US $ 9,836 million obtained in 2023. See Press release the sales of its sclerosis unit […]
Read more
2025-02-11 (globenewswire.com)
Neuroregeneration Therapy Market to Surpass USD 64.8 Billion by 2034, Driven by Advancements in Regenerative Medicine and Rising Neurological Disorders | Transparency Market Research
The global neuroregeneration therapy market is witnessing a surge in demand for innovative therapies, including stem cell therapy, gene therapy, and...
Read more
2025-02-04 (marketbeat.com)
Biogen (BIIB) to Release Earnings on Tuesday |
Biogen (NASDAQ:BIIB) will be releasing earnings before the market opens on Tuesday, February 11, Financial Modeling Prep reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=658031)
Read more
2025-02-03 (openpr.com)
Tardive Dyskinesia Treatment Market Report Analysis and Research Studies, Comprehensive Insights and Key Players - Pfizer Inc., Biogen, Novartis AG.
Press release - DataM Intelligence 4Market Research - Tardive Dyskinesia Treatment Market Report Analysis and Research Studies, Comprehensive Insights and Key Players - Pfizer Inc., Biogen, Novartis AG. - published on openPR.com
Read more